Despite bullish markets, Johnson & Johnson's stock price has declined over 4% year-to-date.Investors eagerly anticipate next week's earnings for insights into Johnson & Johnson's performance.
Investor attention is now turning to the upcoming quarterly results, set to be published next Tuesday. These results present an opportunity for Johnson & Johnson stock to reverse the downtrend, provided the number exceeds forecasts.This company specializes in therapies to break down calcification in arteries, reducing the risk of heart attacks.
If the final readings match forecasts, it will mean a decrease from last year's figures, when earnings per share stood at $2.68 and revenues reached $24.746 billion. This negative outlook contributes to the ongoing selling pressure on the stock.The downward trend that started last month continues, with a high probability of dipping below the $150 per share mark. If sellers succeed in this move, the primary scenario is to target last year's lows of around $145 per share.